Rep. Lisa C. McClain Sells Novo Nordisk A/S (NYSE:NVO) Stock

Representative Lisa C. McClain (R-Michigan) recently sold shares of Novo Nordisk A/S (NYSE:NVO). In a filing disclosed on November 21st, the Representative disclosed that they had sold between $1,001 and $15,000 in Novo Nordisk A/S stock on October 30th. The trade occurred in the Representative’s “CHARLES SCHWAB BROKERAGE ACCOUNT 924” account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Alibaba Group (NYSE:BABA) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Coherent (NYSE:COHR) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Clorox (NYSE:CLX) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Northern Trust (NASDAQ:NTRS) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Honda Motor (NYSE:HMC) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Home BancShares (NYSE:HOMB) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Five Below (NASDAQ:FIVE) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Pure Storage (NYSE:PSTG) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of BHP Group (NYSE:BHP) on 10/31/2025.

Novo Nordisk A/S Stock Up 3.6%

Shares of NVO traded up $1.69 during midday trading on Thursday, reaching $48.75. 17,778,399 shares of the company were exchanged, compared to its average volume of 13,093,955. The stock has a 50-day moving average price of $53.32 and a 200-day moving average price of $59.93. The company has a market cap of $217.67 billion, a price-to-earnings ratio of 13.39, a P/E/G ratio of 2.33 and a beta of 0.65. The company has a current ratio of 0.78, a quick ratio of 0.56 and a debt-to-equity ratio of 0.52. Novo Nordisk A/S has a 1-year low of $43.08 and a 1-year high of $112.52.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, topping analysts’ consensus estimates of $0.77 by $0.25. The firm had revenue of $11.79 billion during the quarter, compared to analysts’ expectations of $11.98 billion. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. Novo Nordisk A/S has set its FY 2025 guidance at EPS. Research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Wall Street Analysts Forecast Growth

NVO has been the subject of several research analyst reports. Jefferies Financial Group initiated coverage on Novo Nordisk A/S in a research note on Monday, October 27th. They set an “underperform” rating for the company. HSBC downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday. Hsbc Global Res lowered Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research report on Monday. BMO Capital Markets dropped their target price on Novo Nordisk A/S from $50.00 to $46.00 and set a “market perform” rating on the stock in a report on Tuesday. Finally, UBS Group downgraded shares of Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Novo Nordisk A/S currently has a consensus rating of “Hold” and an average target price of $57.40.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Revolve Wealth Partners LLC raised its stake in Novo Nordisk A/S by 8.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock valued at $214,000 after purchasing an additional 200 shares during the last quarter. J.W. Cole Advisors Inc. raised its position in shares of Novo Nordisk A/S by 58.3% during the first quarter. J.W. Cole Advisors Inc. now owns 16,266 shares of the company’s stock valued at $1,129,000 after buying an additional 5,989 shares during the last quarter. AE Wealth Management LLC lifted its stake in shares of Novo Nordisk A/S by 20.8% in the first quarter. AE Wealth Management LLC now owns 5,742 shares of the company’s stock valued at $399,000 after buying an additional 989 shares during the period. Pinnacle Associates Ltd. lifted its stake in shares of Novo Nordisk A/S by 2.6% in the first quarter. Pinnacle Associates Ltd. now owns 42,530 shares of the company’s stock valued at $2,953,000 after buying an additional 1,063 shares during the period. Finally, Carnegie Investment Counsel grew its position in Novo Nordisk A/S by 37.2% during the first quarter. Carnegie Investment Counsel now owns 272,475 shares of the company’s stock worth $17,362,000 after buying an additional 73,930 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.

Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.